Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Advent

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

- PMLiVE

Sanofi and Merck & Co dissolve longstanding vaccines alliance

Lacklustre sales at Sanofi Pasteur MSD prompts split

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

dengue fever mosquito

Sanofi embarks on Zika vaccine hunt

Begins research programme as WHO declares the virus a global emergency

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

- PMLiVE

Sanofi abandons inhaled insulin pact with Mannkind

Poor sales prompt return of Afrezza rights less than a year after its launch

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links